Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile ‌obesity drug from its recent $10 billion Metsera purchase that raises ‌questions about its tolerability for patients, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results